Exhibit 107
Calculation of Filing Fee Tables
Form S-1/A | ||
(Form Type) |
CHEMOMAB THERAPEUTICS LTD. | ||
(Exact Name of Registrant as Specified in its Charter) |
Table 1: Newly Registered and Carry Forward Securities
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Maximum Aggregate Offering Price(1)(2) | Fee Rate | Amount of Registration Fee | |||||||||||
Newly Registered Securities | ||||||||||||||||
Fees to be Paid | Equity | Ordinary shares, no par value, as represented by American Depositary Shares | (1) | $ | 20,700,000.00 | $ | .0001102 | $ | 2,281.14 | |||||||
Fees to be Paid | Equity | Pre-Funded Warrants to purchase on American Depositary Share (3) | (4) | |||||||||||||
Fees to be Paid | Equity | American Depositary Shares issuable upon exercise of Pre-Funded Warrants (3) | (1) | |||||||||||||
Total Offering Amounts | $ | 20,700,000.00 | $ | 2,281.14 | ||||||||||||
Total Fees Previously Paid | $ | 3,306.00 | ||||||||||||||
Total Fee Offsets | - | |||||||||||||||
Net Fee Due | $ | 0.00 |
(1) | Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. | |
(2) | Each ADS represents twenty (20) ordinary shares of the registrant. ADSs issuable upon deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-229522). | |
(3) | The registrant may issue pre-funded warrants to purchase ADSs in the offering. The purchase price of each pre-funded warrant will equal the price per share at which ADSs are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.001 per share (subject to adjustment as provided for therein). The proposed maximum aggregate offering price of the ADSs proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants offered and sold in the offering, and the proposed maximum offering price of the pre-funded warrants to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ADSs sold in the offering. | |
(4) | No fee pursuant to Rule 457(g) of the Securities Act. |